Related Experiment Video
Updated: Aug 12, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Upper gastrointestinal bleeding associated with antiplatelet drugs
L Ibáñez1, X Vidal, L Vendrell
1Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Spain.
Alimentary Pharmacology & Therapeutics
|January 6, 2006
Summary
The risk of upper gastrointestinal bleeding from antiplatelet drugs is reduced by proton pump inhibitors. Combining aspirin with a proton pump inhibitor appears safer than using ticlopidine or clopidogrel alone.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- The gastrointestinal bleeding risks associated with antiplatelet medications are not fully understood.
- Gastroprotective agents' effectiveness in preventing these bleeds requires further definition.
Purpose of the Study:
- To quantify the upper gastrointestinal bleeding risk linked to various antiplatelet drugs.
- To assess the efficacy of gastroprotective agents in mitigating these risks.
Main Methods:
- A case-control study design was employed.
- 2813 cases of upper gastrointestinal bleeding were compared with 7193 matched controls.
- Odds ratios for individual antiplatelet drugs were calculated, adjusting for confounders.
Main Results:
- Cardiovascular acetylsalicylic acid showed a significantly increased risk (OR 4.0).
- Ticlopidine (OR 3.1) and clopidogrel (OR 2.3) also presented elevated risks.
- Proton pump inhibitors notably reduced bleeding risks; aspirin plus a PPI had an OR of 1.1.
Conclusions:
- Concomitant proton pump inhibitor use substantially lowers upper gastrointestinal bleeding risk.
- The combination of acetylsalicylic acid and a proton pump inhibitor appears to carry a lower risk than ticlopidine or clopidogrel monotherapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:30Peptic Ulcer Disease I: Introduction
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:28Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...